Precision Biologics — Safer Therapies

---

Our mission is to develop a new class of highly-selective biologic drugs that effectively address the ongoing challenges of side-effects that are limiting the benefits of current treatments in difficult-to-drug diseases.

The approach leverages large libraries of engineered proteins, Selektides, based on a small and hyper-stable human protein scaffold with unique drug properties. 

The drug discovery platform is based on a state-of-the-art combinatorial approach, powered by proprietary selection and computational strategies with AI-guided structure and function analysis, ultimately validated with high resolution Cryo-EM and in vivo studies.

SelekTx is focused on the discovery of highly selective therapeutic molecules targeting G Protein-coupled Receptors (GPCRs) with a platform proven to have broad applicability (Linse et al., PNAS USA 2022).

SelekTx will enter collaboration or licensing arrangements to advance our lead candidates from IND-enabling through clinical trials.

The SelekTx research and development team is active across two laboratories located at UCD, Ireland and Lund University, Sweden. 

A team of full-time 6 research scientists are dedicated to Selektide discovery and development with a primary focus on GPCRs. 

The teams are actively engaged in method development to expand the capabilities of proprietary libraries, cell line panels and biochemical tools, computational analysis methods, high throughput binding kinetics, and  Cryo-EM advancement of Selektide/Target complex visualisation.

These capabilities reflect a level of technical depth more typically associated with later-stage biotechnology companies.